Browse drugs

…eceiving upadacitinib, upadacitinib/elsubrutinib and placebo to upadacitinib/elsubrutinib were maintained or increased from weeks 48 to 104 …

…59/81 (72.8%) (AO)/43/327 (13.1%) and 55/327 (16.8%) (NRI) with adalimumab. Initial non-responders/incomplete responders benefited from sw…

…al remission rates after 5 years were 40.8%, 26.5% and 28.0% on upadacitinib 7.5, 15 and 30 mg, respectively (non-responder imputation).Conc…

…Introduction Upadacitinib is an oral, selective Janus Kinase 1 (JAK1) inhibitor approved …

…dalimumab,50% Vedolimumab,66%(n=4) had Ustekinumab,66%(n=4) had Azathioprine. All patients received UPA as monotherapy.UPA induction was adm…

…Upadacitinib is a selective Janus kinase-1 inhibitor with proven efficacy in…

…-COMPARE, SELECT-PsA 1) assessed the effects of upadacitinib or adalimumab versus placebo on pain in patients with attenuation of inflamma…

…t-to-treat inflammatory bowel disease (DTT-IBD) is challenging. Upadacitinib, an oral Janus kinase 1 inhibitor, has demonstrated efficacy in…

…numab 300 mg biweekly; and -44.15% (95% CI -50.44 to -37.86) vs baricitinib 2 mg diary. Statistically significant differences were found be…

…ents received upadacitinib(47.7%), 15 tofacitinib(34.1%), and 8 filgotinib(18.2%). Thirteen patients (29,5%) received concomitant treatmen…

…world study reporting outcomes in patients with CD treated with upadacitinib. Our data demonstrated good short-term effectiveness and tolera…

…itiated for uveitis and SSc-related manifestations, followed by upadacitinib to address AS activity and potential benefit for SSc. After thr…